This week, Congressional oversight of prescription drug prices will continue with two hearings in the Senate Special Committee on Aging, which is led by Sen. Susan Collins (R-ME) and Bob Casey (D-PA). The hearings will offer a patient perspective as well as the perspective of experts in the field. The Aging Committee does not typically headline major drug pricing hearings, but they have played a key role in this issue before, namely the 2015-2016 bipartisan investigation into dramatic price increases of several pharmaceutical companies.